The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention

Mise à jour : Il y a 4 ans
Référence : NCT00133731

Femme et Homme

Extrait

The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability, clinical efficacy and pharmacokinetics.


Critère d'inclusion

  • Angioplasty, Transluminal, Percutaneous Coronary


Liens